August 2014 Vol 7, Special Issue ASCO 2014 Payers' Perspectives in Oncology

Payers' Perspectives

Stakeholder Integration Needed to Address a Flawed Reimbursement System

Matthew Mitchell, PharmD, MBA, FAMCP

ALTTO: Dual Anti-HER2 Adjuvant Therapy No Better than Trastuzumab Alone

Less May Be “More” with Zoledronic Acid

Caroline Helwick

Adjuvant Exemestane More Effective than Tamoxifen in Early-Stage Breast Cancer

Multiple Myeloma

Novel Drug Classes Make News in Multiple Myeloma

Caroline Helwick

Federal Spending on Cancer Research and Access to Care Woefully Inadequate

Payment Reform Key to Value-Based Cancer Care

Ibrutinib Outperforms Ofatumumab in Patients with Relapsed/Refractory CLL

Caroline Helwick

Emerging Therapies

2014 Oncology Pipeline Looks Impressive

Caroline Helwick, Wayne Kuznar

Patients with Cancer Are Not Asking for Costly, Excessive Treatments

1
2
3
4

Page 1 of 4
Results 1 - 10 of 32

Copyright © Engage Healthcare Communications, LLC. All rights reserved.